Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)

    Predicts overall and progression-free survival in DLBCL based on risk factors.

    INSTRUCTIONS

    Note: IPI results are included for historical comparisons only. Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.

    When to Use
    Pearls/Pitfalls
    Why Use

    Use in CD20+ DLBCL patients. Do not use in patients with HIV, secondary malignancies, low grade lymphoproliferative disorders, or comorbidities precluding curative therapy attempt.

    • The International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI) estimates 4-year progression-free survival and 4-year overall survival for patients with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL).
    • The R-IPI provides greater discrimination amongst DLBCL patients with differing survival based on easily obtained factors.
    • Does not identify any risk group with 4-year survival <50%; hence, other molecular or genetic markers are being researched to help select the worst-outcome patients for alternative treatment/clinical trials.

    Using the same criteria as the older International Prognostic Index (IPI), the revised IPI (R-IPI) discriminates among three different prognostic groups (versus two by IPI), providing more clinical relevance.

    ≤60 years
    0
    >60 years
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Laurie H. Sehn

    About the Creator

    Laurie H. Sehn, MD, is a medical oncologist at the British Columbia Cancer Agency and a clinical associate professor at the University of British Columbia. She is on the Board of Directors and is the director of research fellowships for the Lymphoma Foundation Canada (LFC). Dr. Sehn is an active researcher studying aspects of lymphoid cancers.

    To view Dr. Laurie H. Sehn's publications, visit PubMed

    Are you Dr. Laurie H. Sehn? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    About the Creator
    Dr. Laurie H. Sehn
    Are you Dr. Laurie H. Sehn?
    Content Contributors